Schuck_1999_Therapie_54_237

Reference

Title : [Adverse effects and drugs for Alzheimer's disease] - Schuck_1999_Therapie_54_237
Author(s) : Schuck S , Bentue-Ferrer D , Beaufils C , Polard E , Belliard S , Allain H
Ref : Therapie , 54 :237 , 1999
Abstract :

Molecules currently available or in late phases of development for the treatment of Alzheimer's disease have modest and apparently equivalent efficacies. Thus, the choice will depend on the safety profile of these drugs and on the patient characteristics. The aim of this review is to undertake an inventory of adverse effects and interactions reported in the literature for anticholinesterasics (the only ones approved by authorities). As most of the molecules described in this article are still in early phases of development, data reported here mainly issued from clinical trials carried out on specific populations. Most of these reported adverse effects have not been attributed according to the rules of pharmacovigilance. Nevertheless, we believe that the data presented in this review will be of great interest to clinicians and pharmacovigilance specialists as the compounds concerned become available on the market.

PubMedSearch : Schuck_1999_Therapie_54_237
PubMedID: 10394260

Related information

Citations formats

Schuck S, Bentue-Ferrer D, Beaufils C, Polard E, Belliard S, Allain H (1999)
[Adverse effects and drugs for Alzheimer's disease]
Therapie 54 :237

Schuck S, Bentue-Ferrer D, Beaufils C, Polard E, Belliard S, Allain H (1999)
Therapie 54 :237